| Anderson-Fabry disease: long-term echocardiographic follow-up under enzyme replacement therapy. | |
| | |
MedLine Citation:
|
PMID: 18490303 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIMS: Anderson-Fabry disease affects various organ systems due to glycosphingolipid accumulation. Enzyme replacement therapy (ERT) has been reported to decrease left ventricular wall thickening (LVWT) and to improve diastolic dysfunction. METHODS AND RESULTS: This prospective study included 29 patients (patients; mean age 37 +/- 13 years) with genetically, enzymatically and/or biopsy-proven Anderson-Fabry disease and long-time ERT. Data on symptoms, cardiac medications and history of hypertension were collected and all patients had comprehensive echocardiographic examination prior to ERT and at follow-up. Disease was at an early stage with a total mean Mainz severity score index of only 18.6 +/- 13.0. Prior to ERT, 79% of patients reported acroparesthesia. The median creatinine level was 121 +/- 108 mcmol/L and LVWT was present in nine patients (31%). Binary appearance of the interventricular septum was found in 20% and posterobasal fibrosis in 83%. At median follow-up of 37 months, acroparesthesia decreased to 55% (P = 0.016). There was no change in creatinine levels. The incidence of LVWT was unchanged, only an increase in interventricular septal wall thickness from 11.7 +/- 0.4 to 12.5 +/- 0.5 was observed (P = 0.009). Left atrial size and the percentage of patients with binary appearance and posterobasal fibrosis were unchanged. There was a small improvement in diastolic function (29% decrease of E/Ea; P < 0.002). CONCLUSION: Our Anderson-Fabry cohort had successful long-time ERT with impressive amelioration of subjective symptoms. Although there was not much improvement in cardiac changes apart from a slight improvement of diastolic function, at least, there was no progression of cardiac disease. For complete reversibility of cardiac changes in Anderson-Fabry disease, ERT might have to be started earlier in life and/or prescribed for a longer time. |
| | |
Authors:
|
T Kovacevic-Preradovic; M Zuber; C H Attenhofer Jost; U Widmer; B Seifert; G Schulthess; A Fischer; R Jenni |
Related Documents
:
|
20357153 - Accuracy of preoperative electrocardiographic and chest radiographic screening for pred... 630963 - Disproportionate ventricular thickening in patients with systemic hypertension. 8602753 - Leigh syndrome: clinical features and biochemical and dna abnormalities. |
Publication Detail:
|
Type: Comparative Study; Journal Article Date: 2008-04-14 |
Journal Detail:
|
Title: European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology Volume: 9 ISSN: 1532-2114 ISO Abbreviation: Eur J Echocardiogr Publication Date: 2008 Nov |
Date Detail:
|
Created Date: 2008-10-24 Completed Date: 2009-01-09 Revised Date: 2009-05-20 |
Medline Journal Info:
|
Nlm Unique ID: 100890618 Medline TA: Eur J Echocardiogr Country: England |
Other Details:
|
Languages: eng Pagination: 729-35 Citation Subset: IM |
Affiliation:
|
Division of Cardiology, Cardiovascular Center, University Hospital Zurich, Zurich, Switzerland. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Cohort Studies Drug Therapy, Combination Echocardiography* Fabry Disease / drug therapy*, ultrasonography* Female Follow-Up Studies Humans Isoenzymes / therapeutic use* Male Middle Aged Prospective Studies Severity of Illness Index Treatment Outcome alpha-Galactosidase / therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Isoenzymes; EC 3.2.1.-/agalsidase alfa; EC 3.2.1.-/agalsidase beta; EC 3.2.1.22/alpha-Galactosidase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Concordance between M-mode, pulsed Tissue Doppler, and colour Tissue Doppler in the assessment of mi...
Next Document: Tissue Doppler strain-mapping in the assessment of the extent of chronic myocardial infarction: vali...